Trial · NCT04465968
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-year overall survival rate (3y-OS) | 3 years | 3-year overall survival rate |
| Secondary | 3-year progression-free survival rate (3y-PFS) | 3 years | 3-year progression-free survival rate |
| Secondary | 5-year progression-free survival rate (5y-PFS) | 5 years | 5-year progression-free survival rate |
| Secondary | 5-year overall survival rate (5y-OS) | 5 years | 5-year overall survival rate |
| Secondary | Mode of recurrence | 5 years | Mode of recurrence in surgical cases |
| Secondary | Local recurrence rate | 5 years | Proportion of local failure in surgical cases |
| Secondary | Objective response rate (ORR) | 1 year 6 months | Objective response rate according to RECIST and iRECIST |
| Secondary | Resection rate | 1 year 6 months | Proportion of surgical cases |
| Secondary | Pathological complete resection rate (R0 rate) | 1 year 6 months | Proportion of pathologcal complete resection in surgical cases |
| Secondary | Pathological complete response rate (pCR rate) | 1 year 6 months | Proportion of pathologcal complete response in surgical cases |
| Secondary | Major pathological response rate (MPR rate) | 1 year 6 months | Determination of major pathologic response rate is based on the method by Hellmann et al. on the pathological section. The percentage of residual tumor cells is calculated as viable tumor cells / tumor area × 100 (%). Tumor area includes viable tumor cells and interstitial tissue such as fibrosis, necrosis, and inflammatory cells. |
| Secondary | Operation time | 1 year 6 months | Operation time in surgical cases |
| Secondary | Blood loss | 1 year 6 months | Intraoperative blood loss in surgical cases |
| Secondary | Adverse event rate | 1 year 6 months | |
| Secondary | Incidences of serious adverse events | 1 year 6 months | |
| Secondary | Incidences of adverse events | 1 year 6 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04465968/registered